-
公开(公告)号：US11230572B2
公开(公告)日：2022-01-25
申请号：US16342866
申请日：2017-10-17
摘要： The invention features immunogenic compositions and vaccines containing an optimized human immunodeficiency virus (HIV) envelope (Env) polypeptide (e.g., a stabilized trimer of optimized HIV Env polypeptides) or a polynucleotide encoding an optimized HIV Env polypeptide and uses thereof. The invention also features methods of treating and/or preventing a HIV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).
-
公开(公告)号：US20200377576A1
公开(公告)日：2020-12-03
申请号：US16887710
申请日：2020-05-29
申请人： Massachusetts Institute of Technology , The General Hospital Corporation , Beth Israel Deaconess Medical Center, Inc.
发明人： Darrell J. Irvine , Dan H. Barouch , Arup K. Chakraborty , Dariusz Murakowski , Bruce D. Walker , John Barton , Andrew Ferguson
摘要： Disclosed herein are methods and compositions for treating a subject having or at risk of having an HIV infection. Disclosed herein are peptide immunogens and nucleic acids that have epitopes in which mutations are most likely to have deleterious effects on the HIV virus. An algorithm is disclosed for the selection of the epitopes based on the HIV fitness landscape, and it accounts for the effect of coupling mutations.
-
公开(公告)号：US20230000973A1
公开(公告)日：2023-01-05
申请号：US17808348
申请日：2022-06-23
发明人： Dan H. Barouch , Boris D. Juelg , Maria Grazia Pau , Frank Tomaka
摘要： Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods involve initial administration of an adenovirus vector vaccine and subsequent administration of a poxvirus vector vaccine, followed by administration of anti-HIV broadly neutralizing antibodies (bNAb).
-
公开(公告)号：US11331386B2
公开(公告)日：2022-05-17
申请号：US16948257
申请日：2020-09-10
IPC分类号： A61K39/00 , A61K39/12 , A61K39/21 , C07K14/005 , C07K14/16 , A61K39/235 , A61K39/275 , C12N7/00
摘要： The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
-
15.发明申请公开(公告)号：US20210317169A1
公开(公告)日：2021-10-14
申请号：US17304557
申请日：2021-06-23
IPC分类号： C07K14/005 , A61K39/21 , C07K14/16 , A61K39/12
摘要： The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
-
16.发明授权公开(公告)号：US11059863B2
公开(公告)日：2021-07-13
申请号：US16177573
申请日：2018-11-01
IPC分类号： C07K14/16 , C07K14/005 , A61K39/21 , A61K39/12 , A61K39/00
摘要： The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
-
公开(公告)号：US10781427B2
公开(公告)日：2020-09-22
申请号：US16159336
申请日：2018-10-12
发明人： Dan H. Barouch , Herbert Virgin, IV , Peter Abbink
摘要： The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
-
公开(公告)号：US10772952B2
公开(公告)日：2020-09-15
申请号：US16441703
申请日：2019-06-14
IPC分类号： A61K39/00 , A61K39/12 , C12N7/00 , C07K14/005 , C07K14/025 , A61K39/21 , A61K39/235 , A61K39/275
摘要： The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
-
19.发明授权公开(公告)号：US09932370B2
公开(公告)日：2018-04-03
申请号：US14149549
申请日：2014-01-07
IPC分类号： A61K39/21 , C07K14/005 , C07K14/16 , A61K39/12 , A61K39/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/55505 , A61K2039/55561 , A61K2039/55566 , C07K14/162 , C12N2740/16034 , C12N2740/16111
摘要： The invention features isolated human immunodeficiency virus (HIV) envelope (Env) trimers, in which the amino acid sequence of the Env polypeptides is optimized to stabilize formation of the trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
-
公开(公告)号：US11845788B2
公开(公告)日：2023-12-19
申请号：US17057444
申请日：2019-05-22
发明人： Dan H. Barouch , Bruce A. Kerwin , Randal R. Ketchem , Alison J. Gillespie , Christine C. Siska , Rutilio H. Clark , Julee A. Floyd , Jeremy M. Shaver , Richard S. Rogers
CPC分类号： C07K16/1045 , A61K39/42 , A61K45/06 , A61K2039/505 , C07K2317/14 , C07K2317/41 , C07K2317/76 , C07K2317/94
摘要： Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.031 秒)
